Evaluation of the Performance of the Motus Cleansing System (MCS)

Total of 47 subjects are planned to be enrolled at 3 clinical sites (1 in Germany and 2 in the Netherlands).

Subjects who meet the eligibility criteria will be screened for study participation at a baseline visit(visit 1). Subject who is eligible to the study will required to follow a specific reduced preparation instruction starting 2 days prior to the colonoscopy with the Motus Cleansing System (MCS) procedure.

Following the procedure a telephone follow-up will be conducted at 48 hours (± 24 hours) and 14 days (± 3 days) post MCS procedure to assess patient well-being and capture any Adverse Events (AE).

Inclusion criteria

• Subjects being considered for diagnostic, screening or surveillance colonoscopy
• Subjects in the age range of 18-75 years inclusive
• Subjects with BodyMass Index (BMI) within the range of 18.5-35 inclusive
• Subject has signed the informed consent

Exclusion criteria

• Subjects with known Inflammatory Bowel Disease
• Subjects with known diverticulitis disease or with prior incomplete colonoscopy due to diverticular disease
• Subjects with known or detected (during colonoscopy) bowel obstruction
• History of prior surgery to colon and/or rectum
• ASA≥IV
• Renal insufficiency (Creatinine ≥ 1.5mg /dL) (based on medical history)
• Abnormal Liver enzymes (ALT/AST ≥ 2 times upper limits of normal) (based on medical history)
• Subjects taking anticoagulants drugs (excluding aspirin) or dual antiplatelet therapy
• Subjects with known coagulation disorder (INR >1.5).
• Subjects treated with H2 receptor antagonists or proton pump inhibitors within the 72 hours prior to consuming the Bisacodyl
• Subjects with active, ongoing lower GI bleeding with hemodynamic instability.
• Subjects with known Mega Colon
• Pregnancy (as stated by patient) or breast feeding
• Subjects with altered mental status/inability to provide informed consent
• Patients who have participated in another interventional clinical study in the last 2 months